Caxton Corp Kura Oncology, Inc. Transaction History

Caxton Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $332,617 - $625,239	-20,406 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.95 - $18.81 $15,073 - $35,663	-1,896 Reduced 8.5%	20,406 $333,000
Q1 2020 May 15, 2020	BUY	$6.45 - $14.04 $45 - $98	7 Added 0.03%	22,302 $222,000
Q4 2019 Feb 14, 2020	SELL	$12.97 - $15.94 $120,257 - $147,795	-9,272 Reduced 29.37%	22,295 $307,000
Q3 2019 Nov 14, 2019	BUY	$14.75 - $20.87 $61,433 - $86,923	4,165 Added 15.2%	31,567 $479,000
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $119,562 - $160,853	8,128 Added 42.17%	27,402 $540,000
Q1 2019 May 14, 2019	SELL	$13.73 - $16.87 $186,096 - $228,655	-13,554 Reduced 41.29%	19,274 $320,000
Q4 2018 Feb 14, 2019	SELL	$10.6 - $17.49 $19,928 - $32,881	-1,880 Reduced 5.42%	32,828 $461,000
Q3 2018 Nov 14, 2018	BUY	$16.65 - $21.85 $304,578 - $399,702	18,293 Added 111.44%	34,708 $607,000
Q2 2018 Aug 14, 2018	BUY	$14.8 - $18.8 $242,942 - $308,602	16,415 New	16,415 $0

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $1.07B
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.